The pharma company said that there were no critical deficiencies and one deficiency cited under the category ‘major'. The company also added that it will respond to the agency with appropriate corrective and preventive actions within the stipulated time.
Biocon added that it remains committed to the quality, safety & efficacy of its products.
Biocon is a global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer, and autoimmune.
The biotech company's consolidated net profit surged 71.1% to Rs 144.40 crore on 21.5% jump in revenue from operations to Rs 2,139.50 crore in Q1 FY23 over Q1 FY22.
